Barclays analyst Steven Valiquette maintained a Buy rating on AmerisourceBergen (ABC – Research Report) today and set a price target of $189.00. The company’s shares closed yesterday at $169.16.
According to TipRanks, Valiquette is an analyst with an average return of -0.8% and a 49.16% success rate. Valiquette covers the Healthcare sector, focusing on stocks such as Centene, AmerisourceBergen, and Brookdale Senior Living.
Currently, the analyst consensus on AmerisourceBergen is a Moderate Buy with an average price target of $185.57, which is a 9.70% upside from current levels. In a report released on April 20, Bank of America Securities also maintained a Buy rating on the stock with a $192.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ABC market cap is currently $33.73B and has a P/E ratio of 21.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.
Read More on ABC:
